Gossamer Bio Inc

NASDAQ:GOSS   3:59:54 PM EDT
9.57
-0.08 (-0.83%)
Products

Gossamer Bio Announces Presentation Of GB004 Phase 1B Clinical

Published: 10/12/2020 12:15 GMT
Gossamer Bio Inc (GOSS) - Gossamer Bio Announces Presentation of Gb004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates.
Gossamer Bio - Gb004 Demonstrated Superior Barrier Protection Compared to Tofacitinib in Pre-clinical Human Monolayer Assay.
Gossamer Bio Inc - Shift-uc Phase 2 Study Active and Screening Patients for Enrollment.